Evidence-based meta-analysis of pharmacotherapy for benign prostatic hypertrophy

International Journal of Urology

Volumn 9, Issue 11, 2002, Pages 607-612

  Ishizuka, Osamu ^a   Nishizawa, Osamu ^a   Hirao, Yoshihiko ^b   Ohshima, Shinichi ^c  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Benign prostatic hypertrophy; Evidence based medicine; Pharmacotherapy

Indexed keywords

ALLYLESTRENOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIANDROGEN; CERNITIN; CHLORMADINONE ACETATE; EVIPROSTAT; FINASTERIDE; GESTONORONE CAPROATE; HACHIMIJIOGAN; NAFTOPIDIL; OXENDOLONE; PARAPROST; PRAZOSIN; TAMSULOSIN; TERAZOSIN; URAPIDIL;

ADVERSE DRUG REACTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; EJACULATION DISORDER; ERECTILE DYSFUNCTION; EVIDENCE BASED MEDICINE; HUMAN; ISCHEMIA; JAPAN; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; URINE FLOW RATE;

ADRENERGIC ALPHA-ANTAGONISTS; ANGIOGENESIS INHIBITORS; EVIDENCE-BASED MEDICINE; HUMANS; JAPAN; MALE; PROSTATIC HYPERPLASIA;

EID: 0036456531     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2002.00539.x     Document Type: Review

References (51)

1. McConnell JD, Barry MJ, Bruskewitz RC et al. Benign Prostatic Hyperplasia: Diagnosis and Treatment. Clinical Practice Guideline. AHCPR Publication, Rockville, 1994.
2. Chatelain C, Denis L, Foo KT et al. Benign prostatic hyperplasia. Plymbridge Distributors Ltd, Plymouth UK, 2001.
3. de la Rosette J, Perachino M, Thomas D et al. Guidelines on Benign Prostatic Hyperplasia. Drukkerij Gelderland bv, Arnhem, 2001.
4. Japan Pharmaceutical Information Center. Drugs in Japan 2002 (25th edn). Jiho Inc, Tokyo, Japan, 2001.
5. Narayan P, Tewari A. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. J. Urol. 1998;160: 1701-6. (Level I.)
6. Hofner K, Claes H, de Reijke TM. Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur. Urol. 1999;36: 335-41. (Level I).
7. Narayan P, Bruskewitz R. A comparison of two phase III multicenter, placebo-controlled studies of tamsulosin in BPH. Adv. Ther. 2000;17: 287-300. (Level I).
8. Schulman CC, Lock TM, Buzelin JM et al. Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia. J. Urol. 2001;166: 1358-63. (Level II).
9. Suzuki Y, Katoh T, Isurugi K et al. The efficacy and safety of terazosin and tamsulosin in patients with urinary disturbance accompanying prostatic hypertrophy. Hinyokika Kiyo 2001;47: 15-21. (Level II).
10. Okada H, Kamidono S, Yoshioka T et al. A comparison study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients. BJU Int. 2000;85: 676-81. (Level II).
11. Lee E, Lee C. Clinical comparison of selective and non-selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: Studies on tamsulosin in a fixed dose and terazosin in increasing doses. BJU 1997;80: 606-11. (Level II).
12. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur. Urol. 1999;36: 1-13. (Level III).
13. Tsuji T. Comparison of prazosin, terazosin and tamsu-losin in the treatment of symptomatic benign prostatic hyperplasia: A short-term open, randomized multicenter study. BPH Medical Therapy Study Group. Benign prostatic hyperplasia. Int. J. Urol. 2000;7: 199-205. (Level II).
14. Okada H, Kawaida N, Ogawa T et al. Tamsulosin and chlormadinone for the treatment of benign prostatic hyperplasia. The Kobe University YM617 Study Group. Scand. J. Urol. Nephrol. 1996;30: 379-85. (Level II).
15. Ohtani M, Kikuchi K, Tsuchiya A et al. A randomized long-term comparative study of clinical efficacy of alpha 1-blocker with or without antiandrogen therapy for benign prostatic hyperplasia: focusing on improvement of I-PSS. Hinyokika Kiyo 2000;46: 791-7. (Level II).
16. Ueki O, Kawaguchi K, Katsumi T et al. Clinical efficacy and reduction effect on prostatic volume of chlormadinone acetate combined with tamsulosin hydrochloride in benign prostatic hyperplasia patients insufficiently treated with tamsulosin hydrochloride only. Hinyokika Kiyo 1998;44: 565-73. (Level V).
17. de Mey C, Michel MC, McEwen J et al. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur. Urol. 1998;33: 481-8. (Level II).
18. Michel MC, Neumann HG, Mehlburger L et al. Does the time of administration (morning or evening) affect the tolerability or efficacy of tamsulosin? BJU Int. 2001;87: 31-4. (Level II).
19. Wolzt M, Fabrizil V, Dorner GT et al. Pharmacokinetics of tamsulosin in subjects with normal and varying degrees of impaired renal function: an open-label single-dose and multiple- dose study. Eur. J. Clin. Pharmacol. 1998;54: 367-73. (Level III).
20. Lowe FC. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: Pharmacodynamic effect. Clin. Ther. 1997; 19: 730-42. (Level II).
21. Yasuda K, Yamanishi T, Tojo M et al. Effect of naftopi-dil on urethral obstruction in benign prostatic hyperplasia: Assessment by urodynamic studies. Prostate 1994; 25: 46-52. (Level V).
22. Yamanaka N, Yamaguchi O, Kameoka H et al. Effect of KT-611 (Naftopidil) on the contraction of human prostatic tissue and its use in benign prostatic obstruction. Hinyokika Kiyo 1991;37: 1759-72. (Level V).
23. Debruyne FM, Witjes WP, Fitzpatrick J et al. The international terazosin trial: A multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. The ITT Group. Eur. Urol. 1996;30: 369-76. (Level I).
24. Lepor H, Williford WO, Barry MJ et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N. Engl. J. Med. 1996; 335: 533-9. (Level I).
25. Roehrborn CG, Oesterling JE, Auerbach S et al. The Hytrin Community Assessment Trial study: A one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Invest Group. Urol. 1996;47: 159-68. (Level I).
26. Akbay E, Bozlu M, Doruk E et al. Effect of terazosin on the lipid profile in patients with symptomatic benign prostatic hyperplasia. Urol. Int. 2001;67: 156-9. (Level III).
27. Tamaki M, Ueda T, Kageyama S. Evaluation serum lipid levels in clinical benign prostatic hyperplasia patients with terazosin monotherapy. Hinyokika Kiyo 1999;45: 827-30. (Level V).
28. Lepor H, Machi G. The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH. Prostate 1992;20: 89-95. (Level V).
29. Savage SJ, Spungen AM, Galea G et al. Combination medical therapy for symptomatic benign prostatic hyperplasia. Can. J. Urol. 1998;5: 578-84. (Level II).
30. Suzuki H, Onishi T, Ikemoto I et al. A randomized comparative study assessing once versus twice a day treatment of benign prostatic hyperplasia with terazosin. Hinyokika Kiyo 2001;47: 77-81. (Level II).
31. Brawer MK, Lin DW, Williford WO et al. Effect of finasteride and/or terazosin on serum PSA. Results of VA Cooperative Study #359. Prostate 1999;39: 234-9. (Level III).
32. Kirby RS. Terazosin in benign prostatic hyperplasia: Effects on blood pressure in normotensive and hypertensive men. BJU 1998;82: 373-9. (Level IV).
33. Becopoulos T, Mitropoulos D, Christofis I. Influence of prostate size on terazosin efficacy. Int. J. Urol. 1997;4: 358-61. (Level III).
34. Kawabe K, Tsuchida S, Shimazaki J et al. Effect on urapidil on benign prostatic hypertrophy: A multicenter, double-blind study. Urol. Int. 1993;50: 27-32. (Level I).
35. Steven ID, Coffey GA, Graham NM et al. The effect of prazosin on patients with symptoms of benign prostatic hypertrophy. Aust. Fam. Physician 1993; 22: 1260-4. (Level I).
36. Chrischilles E, Rubenstein L, Chao J et al. Initiation of nonselective alpha 1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: A retrospective cohort study. Clin. Ther. 2001;23: 727-43. (Level I).
37. Yoshida H, Haraguchi C, Ogawa Y et al. Clinical effects of chlormadinone acetate (Prostal) on patients with prostatic hypertrophy - With reference to estimation of size and weight of prostate by mean s of transrectal ultrasonotomography. Hinyokika Kiyo 1983; 29: 1419-26. (Level III).
38. Kogawa T, Yanagiya H, Takashima T et al. Clinical evaluation of the long-term treatment with chlormadinone acetate in patients with benign prostatic hypertrophy. Hinyokika Kiyo 1993;39: 281-7. (Level V).
39. Iguchi H, Ikeuchi T, Kai Y et al. Influence of anti-androgen therapy for prostatic hypertrophy on lipid metabolism. Hinyokika Kiyo 1994; 40: 215-9. (Level III).
40. Shida K, Koyanagi T, Kawakura K et al. Clinical effects of allylestrenol on benign prostatic hypertrophy by double-blind method. Hinyokika Kiyo 1986;32: 625-48. (Level I).
41. Kumamoto Y, Yamaguchi Y, Sato Y et al. Effects of anti-androgens on sexual function. Double-blind comparative studies on allylestrenol and chlormadinone acetate Part I: Nocturnal penile tumescence monitoring. Hinyokika Kiyo 1990;36: 227-44. (Level II).
42. Kumamoto Y, Yamaguchi Y, Sato Y et al. Effects of anti-androgens on sexual function. Double-blind comparative studies on allylestrenol and chlormadinone acetate Part II: Self-assessment questionnaire method. Hinyokika Kiyo 1990;36: 213-26. (Level II).
43. Tsuji Y, Ariyoshi A, Nakamura H et al. Antiandrogen therapy of benign prostatic hypertrophy: Clinical effects of allylestrenol evaluated by transrectal ultrasonographic measurement. Hinyokika Kiyo 1992;38: 961-6. (Level V).
44. Umeda K. Clinical results and problems of anti-androgen therapy of benign prostatic hypertrophy. Hinyokika Kiyo 1991;37: 1429-33. (Level V).
45. Kurita Y, Masuda H, Suzuki K et al. Transition zone ratio and prostate-specific antigen density as predictors of the response of benign prostatic hypertrophy to alpha blocker and anti-androgen therapy. BJU 1997;80: 78-83. (Level II).
46. Ostri P, Swartz R, Meyhoff HH et al. Antiandrogenic treatment of benign prostatic hyperplasia: A placebo controlled trial. Urol. Res. 1989;17: 29-33. (Level II).
47. Meiraz D, Margolin Y, Lev-Ran A et al. Treatment of benign prostatic hyperplasia with hydroxyprogesterone-caproate: Placebo-controlled study. Urology 1977; 9: 144-8. (Level II).
48. MacDonald R, Ishani A, Rutks I et al. A systematic review of Cernilton for the treatment of benign prostatic hyperplasia. BJU 2000;85: 836-41.
49. Maekawa M, Hishimoto T, Yasumoto R et al. Clinical evaluation of Cernilton on benign prostatic hypertrophy - A multiple center double-blind study with Paraprost. Hinyokika Kiyo 1990;36: 495-516. (Level II).
50. Yamaguchi O, Shiraiwa Y, Kobayashi M et al. Clinical evaluation of effects of prazosin in patients with benign prostatic obstruction. A double-blind, multi-institutional, Paraprost-controlled study. Urol. Int. 1990; 45 (Suppl. 1): 40-6. (Level II).
51. Jardin A, Andersson KE, Chapple C et al. Alpha 1-adrenoceptor antagonist in the treatment of BPH. In: Chatelain C, Denis L, Foo KT et al. (eds). Benign Prostatic Hyperplasia. Plymbridge Distributors Ltd, Plymouth, UK 2001, 459-77.